New Study Uncovers Unprecedented Links Between Liver and Heart Health and the Importance of Doctors’ Prioritizing Liver Health to Promote Heart Health
Oxford, 26 June, 2023 Liver disease, the UK’s third leading cause of premature death, poses a significantly greater threat to human health than previo…
26 Jun 2023
Perspectum and BluMaiden Biosciences Pte. Ltd. (“BluMaiden BioSciences”) Form Strategic Collaboration to Introduce Novel Insights into Clinical Trials
San Francisco, CA – April. 13, 2023. Perspectum is proud to announce a strategic collaboration with Singapore-based BluMaiden Biosciences. Developed to ident…
13 Apr 2023
Perspectum Completes $19 Million Second Close of Series C Funding Led by Oppenheimer & Co. Inc. (“Oppenheimer”)
Perspectum Completes $19 Million Second Close of Series C Funding Led by Oppenheimer & Co. Inc. (“Oppenheimer”) Oxford, UK/Dallas, TX, March 15, …
15 Mar 2023
Perspectum Completes $36 Million First Close of Series C Funding Led by Oppenheimer Holdings
Oxford, UK/Dallas, TX, January 5, 2023 – Perspectum, a precision health company which develops medical imaging tools to improve the diagnoses of metabolic di…
5 Jan 2023
Leading Singaporean Diagnostic Center Increases MRI Capacity to Expand Patient Access to Perspectum’s LiverMultiScan
Oxford, UK Nov. 24, 2022 – Perspectum is pleased to announce that Precious Medical Centre is expanding multiparametric diagnostic imaging services in the reg…
14 Dec 2022
Perspectum and Nuance Collaborate to Scale Access to AI-Enabled Integrated Digital Care Platforms to Improve Patient Care for Metabolic Disease
CHICAGO, IL Nov. 28, 2022 -- Perspectum and Nuance Communications, Inc., a Microsoft company, announced today at the 108th Radiological Society of North Americ…
28 Nov 2022
FDA awards Perspectum major grant for the qualification of its noninvasive diagnostic biomarker to reduce liver biopsy in drug trials
Dallas, TX – September 27, 2022. Perspectum today announced The Food and Drug Administration (FDA) awarded the company a major grant to support the qualifica…
27 Sep 2022
LiverMultiScan shown to be a cost-effective alternative to liver biopsies for monitoring patients with autoimmune hepatitis
Health economics study estimates significant savings for England’s NHS Oxford, U.K. — September 21, 2022. A health economic study performed by NHS Engla…
21 Sep 2022
FDA Grants Clearance to Perspectum’s CoverScan – A New Platform-Based Tool to Assess Multiple Organs in One MRI Scan
Perspectum’s CoverScan Obtains FDA Clearance; Builds on Recent UKCA Marking, Oxford, United Kingdom, May 25, 2022 — On May 19, 2022, the United States Food…
22 May 2022
LiverMultiScan® detected earlier stages of treatable disease in patients with autoimmune hepatitis to allow tailored treatment
OXFORD, England – March 21, 2022. A first-of-its-kind study published in eClinicalMedicine - The Lancet, found that LiverMultiScan cT1 (an MRI-derived non-in…
21 Mar 2022
LiverMultiScan® has achieved nationwide payer coverage for diagnosis and management of NAFLD and other established chronic liver diseases
Dallas, Texas – Effective March 13, 2022. AIM Specialty Health deems LiverMultiScan® medically necessary for evaluating diffuse liver diseases, covering ove…
14 Mar 2022
First patient recruited for multi-year collaborative primary sclerosing cholangitis (PSC) pediatric study using Perspectum’s imaging technology to help predict disease progression and guide patient management
San Francisco, January 27, 2022. Perspectum announced recruitment of the first patient in a multi-center collaborative study to characterize Primary Sclerosing…
27 Jan 2022